Loading…

Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity

Novel 1-(1-benzoylpiperidin-4-yl)­methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phospho...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2019-03, Vol.62 (5), p.2750-2771
Main Authors: Sniecikowska, Joanna, Gluch-Lutwin, Monika, Bucki, Adam, Więckowska, Anna, Siwek, Agata, Jastrzebska-Wiesek, Magdalena, Partyka, Anna, Wilczyńska, Daria, Pytka, Karolina, Pociecha, Krzysztof, Cios, Agnieszka, Wyska, Elżbieta, Wesołowska, Anna, Pawłowski, Maciej, Varney, Mark A, Newman-Tancredi, Adrian, Kolaczkowski, Marcin
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2771
container_issue 5
container_start_page 2750
container_title Journal of medicinal chemistry
container_volume 62
creator Sniecikowska, Joanna
Gluch-Lutwin, Monika
Bucki, Adam
Więckowska, Anna
Siwek, Agata
Jastrzebska-Wiesek, Magdalena
Partyka, Anna
Wilczyńska, Daria
Pytka, Karolina
Pociecha, Krzysztof
Cios, Agnieszka
Wyska, Elżbieta
Wesołowska, Anna
Pawłowski, Maciej
Varney, Mark A
Newman-Tancredi, Adrian
Kolaczkowski, Marcin
description Novel 1-(1-benzoylpiperidin-4-yl)­methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT1A receptor affinity, >1000-fold selectivity versus noradrenergic α1, dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic M1 receptors, and favorable druglike properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)­(4-fluoro-4-(((2-(pyridin-2-yloxy)­ethyl)­amino)­methyl)­piperidin-1-yl)­methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT1A receptor-biased agonists could constitute promising antidepressant drug candidates.
doi_str_mv 10.1021/acs.jmedchem.9b00062
format article
fullrecord <record><control><sourceid>proquest_acs_j</sourceid><recordid>TN_cdi_proquest_miscellaneous_2187957997</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2187957997</sourcerecordid><originalsourceid>FETCH-LOGICAL-a275t-e1e89ed3bba3ed0d824f881adc1b96480563bc2f6a53c13ff27298edc984e81a3</originalsourceid><addsrcrecordid>eNotkctu1DAUhiMEEkPhDVh4OV146kuuy7QMFLWCaijryIlPJh4cO9jO0LDiFXhFHoBnwKWz-iWf3_-5fEnylpINJYxeiM5vDiPIboBxU7WEkJw9S1Y0YwSnJUmfJytCGMMsZ_xl8sr7Q7Rwyvgq-fvJHkGj2i3aPiwQhkWjd-DUUQR1BI9sj-ifX7_XFF-C-WkXPakplqUyOMWLPh_jF2HEqAwg4VEYAG0fghMdaD1r4dAO9lEDSHSjjPAxkl4wtN7ubqKeo7vB-mmwsX1saA2-c9CDc8rs0RdwNlijDMriBNf3tI5hHUzBOnypYpRE9T7WffDohwoD2tl29gHVJigJkwPvhQlYq2-A6i6uo8LyOnnRC-3hzUnPkq_vt_dX1_j284ePV_UtFqzIAgYKZQWSt63gIIksWdqXJRWyo22Vx5NmOW871uci4x3lfc8KVpURQFWmEH38LFk_5U7Ofp_Bh2ZU_vEmwoCdfcNoWVRZUVVFtJIna6TYHOzsTBysoaR5RNv8fzyhbU5o-T90bKHI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2187957997</pqid></control><display><type>article</type><title>Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Sniecikowska, Joanna ; Gluch-Lutwin, Monika ; Bucki, Adam ; Więckowska, Anna ; Siwek, Agata ; Jastrzebska-Wiesek, Magdalena ; Partyka, Anna ; Wilczyńska, Daria ; Pytka, Karolina ; Pociecha, Krzysztof ; Cios, Agnieszka ; Wyska, Elżbieta ; Wesołowska, Anna ; Pawłowski, Maciej ; Varney, Mark A ; Newman-Tancredi, Adrian ; Kolaczkowski, Marcin</creator><creatorcontrib>Sniecikowska, Joanna ; Gluch-Lutwin, Monika ; Bucki, Adam ; Więckowska, Anna ; Siwek, Agata ; Jastrzebska-Wiesek, Magdalena ; Partyka, Anna ; Wilczyńska, Daria ; Pytka, Karolina ; Pociecha, Krzysztof ; Cios, Agnieszka ; Wyska, Elżbieta ; Wesołowska, Anna ; Pawłowski, Maciej ; Varney, Mark A ; Newman-Tancredi, Adrian ; Kolaczkowski, Marcin</creatorcontrib><description>Novel 1-(1-benzoylpiperidin-4-yl)­methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT1A receptor affinity, &gt;1000-fold selectivity versus noradrenergic α1, dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic M1 receptors, and favorable druglike properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)­(4-fluoro-4-(((2-(pyridin-2-yloxy)­ethyl)­amino)­methyl)­piperidin-1-yl)­methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT1A receptor-biased agonists could constitute promising antidepressant drug candidates.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.9b00062</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Journal of medicinal chemistry, 2019-03, Vol.62 (5), p.2750-2771</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-2923-5714 ; 0000-0003-2549-170X ; 0000-0003-0451-9814 ; 0000-0002-5296-7964 ; 0000-0001-8402-1121</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Sniecikowska, Joanna</creatorcontrib><creatorcontrib>Gluch-Lutwin, Monika</creatorcontrib><creatorcontrib>Bucki, Adam</creatorcontrib><creatorcontrib>Więckowska, Anna</creatorcontrib><creatorcontrib>Siwek, Agata</creatorcontrib><creatorcontrib>Jastrzebska-Wiesek, Magdalena</creatorcontrib><creatorcontrib>Partyka, Anna</creatorcontrib><creatorcontrib>Wilczyńska, Daria</creatorcontrib><creatorcontrib>Pytka, Karolina</creatorcontrib><creatorcontrib>Pociecha, Krzysztof</creatorcontrib><creatorcontrib>Cios, Agnieszka</creatorcontrib><creatorcontrib>Wyska, Elżbieta</creatorcontrib><creatorcontrib>Wesołowska, Anna</creatorcontrib><creatorcontrib>Pawłowski, Maciej</creatorcontrib><creatorcontrib>Varney, Mark A</creatorcontrib><creatorcontrib>Newman-Tancredi, Adrian</creatorcontrib><creatorcontrib>Kolaczkowski, Marcin</creatorcontrib><title>Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Novel 1-(1-benzoylpiperidin-4-yl)­methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT1A receptor affinity, &gt;1000-fold selectivity versus noradrenergic α1, dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic M1 receptors, and favorable druglike properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)­(4-fluoro-4-(((2-(pyridin-2-yloxy)­ethyl)­amino)­methyl)­piperidin-1-yl)­methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT1A receptor-biased agonists could constitute promising antidepressant drug candidates.</description><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkctu1DAUhiMEEkPhDVh4OV146kuuy7QMFLWCaijryIlPJh4cO9jO0LDiFXhFHoBnwKWz-iWf3_-5fEnylpINJYxeiM5vDiPIboBxU7WEkJw9S1Y0YwSnJUmfJytCGMMsZ_xl8sr7Q7Rwyvgq-fvJHkGj2i3aPiwQhkWjd-DUUQR1BI9sj-ifX7_XFF-C-WkXPakplqUyOMWLPh_jF2HEqAwg4VEYAG0fghMdaD1r4dAO9lEDSHSjjPAxkl4wtN7ubqKeo7vB-mmwsX1saA2-c9CDc8rs0RdwNlijDMriBNf3tI5hHUzBOnypYpRE9T7WffDohwoD2tl29gHVJigJkwPvhQlYq2-A6i6uo8LyOnnRC-3hzUnPkq_vt_dX1_j284ePV_UtFqzIAgYKZQWSt63gIIksWdqXJRWyo22Vx5NmOW871uci4x3lfc8KVpURQFWmEH38LFk_5U7Ofp_Bh2ZU_vEmwoCdfcNoWVRZUVVFtJIna6TYHOzsTBysoaR5RNv8fzyhbU5o-T90bKHI</recordid><startdate>20190314</startdate><enddate>20190314</enddate><creator>Sniecikowska, Joanna</creator><creator>Gluch-Lutwin, Monika</creator><creator>Bucki, Adam</creator><creator>Więckowska, Anna</creator><creator>Siwek, Agata</creator><creator>Jastrzebska-Wiesek, Magdalena</creator><creator>Partyka, Anna</creator><creator>Wilczyńska, Daria</creator><creator>Pytka, Karolina</creator><creator>Pociecha, Krzysztof</creator><creator>Cios, Agnieszka</creator><creator>Wyska, Elżbieta</creator><creator>Wesołowska, Anna</creator><creator>Pawłowski, Maciej</creator><creator>Varney, Mark A</creator><creator>Newman-Tancredi, Adrian</creator><creator>Kolaczkowski, Marcin</creator><general>American Chemical Society</general><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2923-5714</orcidid><orcidid>https://orcid.org/0000-0003-2549-170X</orcidid><orcidid>https://orcid.org/0000-0003-0451-9814</orcidid><orcidid>https://orcid.org/0000-0002-5296-7964</orcidid><orcidid>https://orcid.org/0000-0001-8402-1121</orcidid></search><sort><creationdate>20190314</creationdate><title>Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity</title><author>Sniecikowska, Joanna ; Gluch-Lutwin, Monika ; Bucki, Adam ; Więckowska, Anna ; Siwek, Agata ; Jastrzebska-Wiesek, Magdalena ; Partyka, Anna ; Wilczyńska, Daria ; Pytka, Karolina ; Pociecha, Krzysztof ; Cios, Agnieszka ; Wyska, Elżbieta ; Wesołowska, Anna ; Pawłowski, Maciej ; Varney, Mark A ; Newman-Tancredi, Adrian ; Kolaczkowski, Marcin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a275t-e1e89ed3bba3ed0d824f881adc1b96480563bc2f6a53c13ff27298edc984e81a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sniecikowska, Joanna</creatorcontrib><creatorcontrib>Gluch-Lutwin, Monika</creatorcontrib><creatorcontrib>Bucki, Adam</creatorcontrib><creatorcontrib>Więckowska, Anna</creatorcontrib><creatorcontrib>Siwek, Agata</creatorcontrib><creatorcontrib>Jastrzebska-Wiesek, Magdalena</creatorcontrib><creatorcontrib>Partyka, Anna</creatorcontrib><creatorcontrib>Wilczyńska, Daria</creatorcontrib><creatorcontrib>Pytka, Karolina</creatorcontrib><creatorcontrib>Pociecha, Krzysztof</creatorcontrib><creatorcontrib>Cios, Agnieszka</creatorcontrib><creatorcontrib>Wyska, Elżbieta</creatorcontrib><creatorcontrib>Wesołowska, Anna</creatorcontrib><creatorcontrib>Pawłowski, Maciej</creatorcontrib><creatorcontrib>Varney, Mark A</creatorcontrib><creatorcontrib>Newman-Tancredi, Adrian</creatorcontrib><creatorcontrib>Kolaczkowski, Marcin</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sniecikowska, Joanna</au><au>Gluch-Lutwin, Monika</au><au>Bucki, Adam</au><au>Więckowska, Anna</au><au>Siwek, Agata</au><au>Jastrzebska-Wiesek, Magdalena</au><au>Partyka, Anna</au><au>Wilczyńska, Daria</au><au>Pytka, Karolina</au><au>Pociecha, Krzysztof</au><au>Cios, Agnieszka</au><au>Wyska, Elżbieta</au><au>Wesołowska, Anna</au><au>Pawłowski, Maciej</au><au>Varney, Mark A</au><au>Newman-Tancredi, Adrian</au><au>Kolaczkowski, Marcin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2019-03-14</date><risdate>2019</risdate><volume>62</volume><issue>5</issue><spage>2750</spage><epage>2771</epage><pages>2750-2771</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Novel 1-(1-benzoylpiperidin-4-yl)­methanamine derivatives were designed as “biased agonists” of serotonin 5-HT1A receptors. The compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization, and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5-HT1A receptor affinity, &gt;1000-fold selectivity versus noradrenergic α1, dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic M1 receptors, and favorable druglike properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)­(4-fluoro-4-(((2-(pyridin-2-yloxy)­ethyl)­amino)­methyl)­piperidin-1-yl)­methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT1A receptor-biased agonists could constitute promising antidepressant drug candidates.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.jmedchem.9b00062</doi><tpages>22</tpages><orcidid>https://orcid.org/0000-0002-2923-5714</orcidid><orcidid>https://orcid.org/0000-0003-2549-170X</orcidid><orcidid>https://orcid.org/0000-0003-0451-9814</orcidid><orcidid>https://orcid.org/0000-0002-5296-7964</orcidid><orcidid>https://orcid.org/0000-0001-8402-1121</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2019-03, Vol.62 (5), p.2750-2771
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_2187957997
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
title Novel Aryloxyethyl Derivatives of 1‑(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5‑HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T02%3A42%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_acs_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Aryloxyethyl%20Derivatives%20of%201%E2%80%91(1-Benzoylpiperidin-4-yl)methanamine%20as%20the%20Extracellular%20Regulated%20Kinases%201/2%20(ERK1/2)%20Phosphorylation-Preferring%20Serotonin%205%E2%80%91HT1A%20Receptor-Biased%20Agonists%20with%20Robust%20Antidepressant-like%20Activity&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Sniecikowska,%20Joanna&rft.date=2019-03-14&rft.volume=62&rft.issue=5&rft.spage=2750&rft.epage=2771&rft.pages=2750-2771&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.9b00062&rft_dat=%3Cproquest_acs_j%3E2187957997%3C/proquest_acs_j%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a275t-e1e89ed3bba3ed0d824f881adc1b96480563bc2f6a53c13ff27298edc984e81a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2187957997&rft_id=info:pmid/&rfr_iscdi=true